• Jingxin Zhang, Wenji Hou, Junbo Zuo, Zhenhua Huang, Xin Ding, and Xuefeng Bu.
• Department of General Surgery, Affiliated People's Hospital of Jiangsu University, Zhenjiang, China.
• Medicine (Baltimore). 2022 Oct 21; 101 (42): e31096e31096.

BackgroundSTAD ranked 5th most common in the incidence of malignant tumors and 3rd most common in the death rate of cancer worldwide. CXC chemokines affect the biological progress of various tumors, resulting in therapeutic failure. The role of CXCL2 in STAD was still a mystery.MethodsThe expression, prognostic value, and clinical function of CXCL2 were analyzed using several online bioinformatics tools and clinical tissues.ResultsCXCL2 level was significantly upregulated in STAD tissues. Strong correlation was obtained between CXCL2 level and immune cells as well as immune biomarkers. High CXCL2 expression in STAD was correlated with a favorable prognosis. Further analysis revealed that CXCL2, pTNM stage and age were independent factors affecting the prognosis of STAD patients. A predictive nomogram indicated that the calibration plots for the 1-year, 3-year and 5-year OS rates were predicted relatively well compared with an ideal model in the entire cohort. Validation analysis revealed that CXCL2 expression was upregulated in STAD and high CXCL2 level had a better overall survival. CXCL2 was associated with resistance to numerous drugs or small molecules in STAD.ConclusionsWe identified CXCL2 as a novel therapeutic target and associated with immune infiltration in STAD.Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc.

9 keywords...

hide…